Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

CGRP as the target of new migraine therapies - successful translation from bench to clinic

Research output: Contribution to journalReviewResearchpeer-review

  1. Calcitonin gene-related peptide - beyond migraine prophylaxis

    Research output: Contribution to journalComment/debateResearchpeer-review

  2. Ageing as a risk factor for neurodegenerative disease

    Research output: Contribution to journalReviewResearchpeer-review

  3. Does inflammation have a role in migraine?

    Research output: Contribution to journalReviewResearchpeer-review

  4. The current role of MRI in differentiating multiple sclerosis from its imaging mimics

    Research output: Contribution to journalReviewResearchpeer-review

  5. Human models of migraine - short-term pain for long-term gain

    Research output: Contribution to journalReviewResearchpeer-review

  1. Exploration of physiological and pathophysiological implications of miRNA-143 and miRNA-145 in cerebral arteries

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Exploration of purinergic receptors as potential anti-migraine targets using established pre-clinical migraine models

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Does inflammation have a role in migraine?

    Research output: Contribution to journalReviewResearchpeer-review

  4. The changing faces of migraine

    Research output: Contribution to journalEditorialResearchpeer-review

  5. Some aspects on the pathophysiology of migraine and a review of device therapies for migraine and cluster headache

    Research output: Contribution to journalReviewResearchpeer-review

View graph of relations

Treatment of migraine is on the cusp of a new era with the development of drugs that target the trigeminal sensory neuropeptide calcitonin gene-related peptide (CGRP) or its receptor. Several of these drugs are expected to receive approval for use in migraine headache in 2018 and 2019. CGRP-related therapies offer considerable improvements over existing drugs as they are the first to be designed specifically to act on the trigeminal pain system, they are more specific and they seem to have few or no adverse effects. CGRP receptor antagonists such as ubrogepant are effective for acute relief of migraine headache, whereas monoclonal antibodies against CGRP (eptinezumab, fremanezumab and galcanezumab) or the CGRP receptor (erenumab) effectively prevent migraine attacks. As these drugs come into clinical use, we provide an overview of knowledge that has led to successful development of these drugs. We describe the biology of CGRP signalling, summarize key clinical evidence for the role of CGRP in migraine headache, including the efficacy of CGRP-targeted treatment, and synthesize what is known about the role of CGRP in the trigeminovascular system. Finally, we consider how the latest findings provide new insight into the central role of the trigeminal ganglion in the pathophysiology of migraine.

Original languageEnglish
JournalNature reviews. Neurology
Volume14
Issue number6
Pages (from-to)338-350
Number of pages13
ISSN1759-4758
DOIs
Publication statusPublished - 2018

ID: 54579877